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UNIT 4.13Cellular Delivery of Locked Nucleic Acids
(LNAs)
This unit describes the introduction of locked nucleic acid (LNA) oligomers (Fig. 4.13.1;
Koshkin et al., 1998; Obika et al., 1998; Wang et al., 1999; reviewed in Braasch and Corey,
2001) into cells. It is intended to extend the discussion of the synthesis and charac-
terization of LNA that is found in UNIT 4.12.
BASIC
PROTOCOL
INTRODUCTION OF LNA OLIGOMERS INTO CELLS
As is the case for most other types of oligonucleotide, there is little reason to believe that
LNA oligomers will be able to spontaneously enter most types of cultured cells and locate
a cellular target. Since LNAs possess a negatively charged backbone, one simple method
for promoting uptake is the use of cationic lipid. A step-wise sample procedure for a
48-well plate format is given below and a schematic summary is provided in Figure 4.13.2.
NOTE: The conditions required for successful transfections will vary from one cell line
to the next. It is impossible to predict which combination of lipid and oligonucleotide will
be most effective; this must be determined empirically for each cell line.
Materials
Cells grown to confluence in 75-cm2 tissue culture flasks
Complete growth medium (see recipe)
100 µM LNA stock solution (see Support Protocol 1)
Opti-MEM I (Invitrogen Life Technologies; reduced-serum medium, containing
L-glutamine and no phenol red)
LipofectAMINE (Invitrogen Life Technologies)
48-well tissue culture plate (Costar)
Repeating pipettor (e.g., Eppendorf)
12.5-mL Combitips (Eppendorf)
65° and 37°C water baths or a thermal cycler
12 × 75–mm round-bottom tubes
37°C, 5% CO2 incubator
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Additional reagents and equipment for trypsinizing and counting cells (e.g., CPMB
APPENDIX 3F)
NOTE: LipofectAMINE and Opti-MEM I are important to the success of the experiment
and should not be substituted.
Prepare cells
1. Beginning with a 75-cm2 tissue culture flask of cells grown to confluence, trypsinize
the cells according to standard procedures (e.g., CPMB APPENDIX 3F).
The total number of cells (and thus the number of flasks) will depend on the number of
LNAs being transfected. For transfection of a single LNA, 33,000 to 39,000 cells are needed
(11,000 to 13,000 cells per well at three different concentrations of LNA-LipofectAMINE
complex).
2. Suspend the cells in fresh complete growth medium.
inhibitor (100 µM LNA) 6.4 µL
1.9 µL
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Figure 4.13.2 Preparation of LipofectAMINE-LNA complexes for cellular transfection, including
subsequent dilutions of stock complexes. Vt = total volume. Volumes are sufficient for dispensing
six replicates and have been optimized for COS-7 cells.





3. Draw up the entire volume of cell suspension into a 10-mL pipet and dispense back
into the flask with the tip of the pipet pressed lightly against the bottom of the flask.
Aggregates of cells will be disrupted, yielding a single-cell suspension that gives more
accurate cell counts.
4. Perform a cell count in triplicate using a Coulter counter or hemacytometer (e.g.,
CPMB APPENDIX 3F) and average the results.
5. Prepare cell suspension in complete growth medium at a density of 44,000 to 52,000
cells/mL.
6. Plate cells 4 to 6 hr prior to transfection. For each LNA to be transfected, plate 250
µL cell suspension (11,000 to 13,000 cells) in three wells of a 48-well tissue culture
plate.
For accuracy with larger numbers of LNAs, use a repeating pipettor and a 12.5-mL
Combitip.
7. Replace cover on plate and disperse cells evenly within the wells by sliding the plate
back and forth, gently bumping it against the front lip of a laminar flow hood work
surface. Keep cells 4 to 6 hr at 37°C in a 5% CO2 incubator for cells to attach to the
surface.
Prepare LNA-LipofectAMINE complexes
8. Warm 100 µM LNA stock solution 5 min at 65°C for a 15-mer or 95°C for a 25-mer
to disrupt aggregates, and then maintain at 37°C until transfection. Also warm
Opti-MEM I to 37°C.
9. In a 12 × 75–mm round-bottom tube, dilute 6.4 µL of 100 µM LNA with 143.6 µL
Opti-MEM I.
10. In a separate 12 × 75–mm round-bottom tube, dilute 1.9 µL LipofectAMINE with
148.1 µL Opti-MEM I.
This solution can be scaled up in a single tube depending on how many unique conditions
are being tested. If, for example, five inhibitors (LNAs) are to be tested, then it would be
advantageous to prepare sufficient lipid mix for seven conditions.
11. Add 150 µL LipofectAMINE from step 10 to each LNA in step 9 (total 300 µL) and
tap the tube briskly 15 times to mix the reagents and initiate the formation of
LNA-LipofectAMINE complexes.
12. Allow the tube to sit 15 min at room temperature in the dark.
Opti-MEM I is light sensitive.
Transfect cells
13. While waiting for complexes to form, aspirate off the complete growth medium in
each well of the tissue culture plate and replace with 250 µL Opti-MEM I per well.
Also set up two tubes for a dilution series of LNA-LipofectAMINE complexes and
add 1.5 mL Opti-MEM I to each.
14. When the incubation (step 12) is complete, add 2.9 mL Opti-MEM I to the LNA-
LipofectAMINE complexes and mix well.
This gives 3.2 mL at 200 nM LNA for the starting concentration for the serial dilution. The
authors typically use 200 nM or 500 nM as the starting concentration.






15. Transfer 1.5 mL stock to one of the tubes in step 13 (final 3 mL at 100 nM) and mix
well. Transfer 500 µL of this solution to the second tube (final 2 mL at 25 mM) and
mix well.
If 500 nM is used as the starting concentration, a 200 nM dilution should be included.
16. Aspirate the Opti-MEM I wash from the cells and immediately dispense 200 µL of
each LNA-LipofectAMINE dilution to the appropriate wells, working backward
through the dilution scheme for a given LNA.
17. Allow cells to incubate overnight at 37°C.
18. Aspirate off transfection solution and replace with 250 µL complete growth medium.
19. Incubate >24 hr at 37°C prior to conducting an assay for the effects of the LNA.
When developing a protocol for delivering LNAs into cells, it is useful to obtain a
fluorophore-labeled LNA. Delivery of the LNA can be visualized by microscopy, facilitating
the evaluation and subsequent optimization of delivery conditions.
SUPPORT
PROTOCOL 1
PREPARATION OF LNA OLIGOMER STOCK SOLUTIONS
LNA oligomers arrive lyophilized and should be handled like DNA or RNA oligomers.
Materials
Locked nucleic acid oligomers (LNAs; Proligo)
DNase/RNase-free water (Life Technologies)
Spectrophotometer
1. If LNAs have been refrigerated, allow them to equilibrate to room temperature.
2. Centrifuge the samples 2 min at 14,000 × g, room temperature, to collect LNA at the
bottom of the tube.
3. Add DNase/RNase-free water to give a stock solution of ∼1 mM. Allow the oligomer
to sit undisturbed for 10 to 15 min at room temperature.
The estimated concentration is based on the volume, on the mass reported by the manufac-
turer, and on the molecular weight of a given LNA.
4. Vortex in 5-sec bursts several times. Heat to 65°C for up to 15 min and cool to room
temperature.
5. Allow tubes to sit undisturbed for 5 min, room temperature.
6. Centrifuge 2 min at 14,000 × g, room temperature, to pellet any remaining undis-
solved material.
Observe the tube contents carefully at this point, as occasionally there are insoluble
materials that can interfere with cellular assays. It is best not to proceed with cellular
assays if an LNA exhibits this behavior unless one has significant experience in desalting
and purifying oligomers. Consult the manufacturer if solubility properties are not satisfac-
tory.
7. Remove a 1-µL aliquot and dilute it with 144 µL distilled water. Ascertain the
absorbance at 260 nm.
8. Calculate the concentration of the LNA using the following equation, where 33 ng/µL
is the extinction coefficient of the LNA and 145 is the dilution factor:
c (mM) = (A260 × 33 ng/µL × 145)/mol. wt. of LNA





The value 33 ng/L assumes an average extinction coefficient based on an equal population
of all bases. If the LNA contains a preponderance of one or two bases, the equation can be
modified (e.g., see CPMB APPENDIX 3D) using the appropriate extinction coefficients. The
extinction coefficients of the LNA nucleotide analogs are not available to the authors, but
it may be reasonable to assume that they are the same as for DNA nucleotides (Proligo,
pers. comm.).
9. Adjust concentration to 100 µM and store the stock solution for up to 1 year at 4°C.
SUPPORT
PROTOCOL 2
DETERMINATION OF Tm FOR LNA OLIGOMERS
To understand the potential for LNA oligonucleotides to recognize intracellular targets,
it is useful to determine Tm values for LNAs with complementary RNA or DNA oligomers.
Materials
LNA oligonucleotides
DNA or RNA oligomers
10× Ca2+- and Mg2+-free phosphate-buffered saline (CMF-PBS; Invitrogen Life
Technologies or see recipe)
0.1 M Na2HPO4 buffer, pH 7.5 (Fisher)
Mineral oil (Sigma)
Stoppered cuvette (1-cm pathlength and 1.5-cm Z dimension; Spectrosil Far UV
Quartz, Uvonic Instruments)
Spectrophotometer with temperature-controlled cuvette holder
1. Calculate the concentration of each of the single-stranded components (LNA and
either DNA or RNA).
The concentration of LNAs can be determined from the A260 value of a diluted aliquot (see
Support Protocol 1, step 8).
It is sometimes useful to heat the LNAs to 65°C or higher, depending on the oligomer length
and the number of LNA bases, to break up intra- and intermolecular hydrogen bonding
and aggregation. When preparing oligonucleotide pairs for Tm analysis or tranfection, it
is prudent to heat the samples and ensure that the concentrations are accurate.
2. Prepare a small volume (∼20 to 30 µL) of 100 µM heteroduplex nucleic acid in a
solution containing 2.5× CMF-PBS final concentration.
3. Dilute a 5-µL aliquot of the 100 µM heteroduplex mixture with 145 µL of 0.1 M
Na2HPO4 buffer, pH 7.5, in a 1-cm-pathlength stoppered cuvette.
4. Overlay this solution with 145 µL mineral oil to minimize evaporation.
5. Monitor the change in the absorbance at 260 nm every 5°C as the temperature is
ramped from 100° to 12°C and also back up to 100°C.
6. Fit the data collected from these analyses using van’t Hoff thermal denatura-
tion/renaturation curve analysis to determine the Tm values from the denaturation and
renaturation curves (UNIT 7.3).
It is not uncommon for entirely LNA oligomers with >11 bases to possess Tm values >95°C.







Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see
APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
CMF-PBS (Ca2+- and Mg2+-free phosphate-buffered saline), 10×
10.4 mM KH2PO4
1551.7 mM NaCl
29.6 mM Na2HPO4⋅7H2O, pH 7.4
Store up to 1 year at 4°C
Complete growth medium
Dulbecco’s modified Eagle’s medium (DMEM) high-glucose without L-glutamine
(e.g., Mediatech Cellgro, Fisher) containing:
20 mM HEPES buffer, pH 7.4 (cell-culture grade, Sigma)
10% (w/v) FBS (Atlanta Biologicals)
1× PSF (see recipe)
0.7 mg/mL tylosin (Sigma)
2 mM L-glutamine (Invitrogen Life Technologies)




25 µg/mL amphotericin B (e.g., Fungizone, Invitrogen Life Technologies)
Store up to 1 year at −20°C
COMMENTARY
Background Information
LNAs offer several advantages for nucleic
acid recognition (Table 4.13.1), which should
encourage investigators to consider their use.
Currently, oligonucleotides that contain LNA
bases can be obtained commercially from
Proligo (http://www.proligo.com). Synthesis is
based on phosphoramidite chemistry and em-
ploys LNA monomers of A, T, G, and 5-methyl-
C.
The most striking advantage conferred by
use of LNA bases is a dramatic increase in the
affinity of binding to complementary se-
quences (Table 4.13.2). A single LNA base can
increase the melting temperature (Tm) of bind-
ing by 10°C, and oligomers that contain several
strategically positioned LNA bases can bind
with even higher affinity than analogous pep-
tide nucleic acid (PNA) oligomers (Braasch
and Elayadi, unpub. observ.). LNA bases are
introduced into oligonucleotides by standard
synthesis methods (UNIT 4.12), allowing LNA
bases to be interspersed among DNA or RNA
bases. As a result, important properties such as
Table 4.13.1 Advantages of Locked Nucleic Acids
High affinity hybridization Tight binding by short LNAs or at high
temperatures
Synthesized like DNA/RNA Enables ready adaptation of existing
synthesizers. Simple to intersperse DNA or
RNA bases to modulate Tm values or RNase H
sensitivity.
Negatively charged backbone Good solubility; investigators who work with
DNA or RNA will find LNA easy to work
with. Ability to incorporate phosphorothioate
linkages to improve stability or
pharmacokinetic properties.





Tm or RNase H activation can be tailored to
meet the specifications of individual applica-
tions. This combination of high-affinity hy-
bridization with standard synthesis protocols is
powerful because it encourages adapting LNAs
to existing protocols that use oligonucleotides.
Critical Parameters
When designing oligonucleotides that are
intended to function inside cells, the ability of
the oligonucleotides to form duplexes that act
as substrates for RNase H is a primary consid-
eration (Crooke, 1999). RNase H degrades
RNA-DNA hybrids, allowing oligonucleotides
that contain DNA to promote the cleavage of
mRNA. If antisense inhibition of gene expres-
sion is desired, this can be an advantage since
the target mRNA is permanently inactivated,
and the antisense oligomer can then move on
to inactivate additional mRNA molecules. Oli-
gonucleotides that cannot recruit RNase H (i.e.,
that do not contain DNA portions) can block
the binding of the translation apparatus when
targeted to the 5′ terminus of the untranslated
region (Baker et al., 1997; Doyle et al., 2001).
Oligomers that do not activate RNase H can
also redirect splicing when targeted to splice
sites (Kang et al., 1998), but when they are
targeted to other mRNA sequences, they are
likely to be displaced by the ribosome.
Oligomers that contain only LNA bases ac-
tivate RNase H poorly (Wahlestedt et al., 2000).
However, because LNAs are made using pro-
tocols similar to those used for DNA synthesis,
it is straightforward to incorporate DNA bases
into LNA-DNA chimera. This provides the
experimenter with the choice of whether or not
to incorporate RNase H sensitivity into oli-
gonucleotide design by including a contiguous
run of at least six DNA bases. If antisense gene
inhibition is desired, this strategy may allow a
wider range of sequences to be targeted. If
simple steric blocking of the RNA target is
required, the potential to direct RNase H cleav-
age is unnecessary and even counterproductive
because it might lead to unintentional destruc-
tion of nontargeted RNA substrates.
LNA bases confer some increase in the sta-
bility of oligomers to degradation by nucleases.
However, to achieve maximal stability in ani-
mal studies, it is likely that one or two phos-
phorothioate (PS) linkages will need to be sub-
stituted at both the 3′- and 5′-terminal linkages.
As noted above, LNA synthesis is similar to the
Table 4.13.2 Melting Temperature (Tm) Values for LNAs and LNA-DNA Hybrids
LNA or LNA-DNAa Tm Tm(ref)b ∆Tm ∆Tm/LNAbase Reference
GTGTTTTGC 52 28 24 5 Kumar et al. (1998)
GTGTCCGAGACGTTG 72 59 13 1.5 Wahlstedt et al. (2000)
GTGTCCGAGACGTTG 83 59 24 3 Wahlstedt et al. (2000)
GTGTCCGAGACGTTG >90 59 >31 2 Wahlstedt et al. (2000)
CACTATACG 40 29 11 3.3 Koshkin et al. (1998)
CTGATATGC 36.8 27.2 9.6 9.6 Bondensgaard et al. (2000)
CTGATATGC 51.6 27.2 24.4 8.1 Bondensgaard et al. (2000)
AGGGTCGCTmeCGGTGT >96 53 43 3 Braasch (unpub. observ.)
AGGGTCGCTmeCAATGT 83 NPc — — Braasch (unpub. observ.)
meCAGTTAGGGTTAG 81 50 31 3.1 Braasch (unpub. observ.)
meCAGTTAGAATTAG 65 NPc — — Braasch (unpub. observ.)
TAGGGT 56 NDc — — Braasch (unpub. observ.)
TAGGGTTA 74 22 52 6.5 Braasch (unpub. observ.)
AGGATmeCTAGGTGAA >96 53 25 2.9 Braasch (unpub. observ.)
AGGATmeCTAGG 73 39 34 3.4 Braasch (unpub. observ.)
AGGATmeCTAGGTGAA 59 53 6 0.6 Braasch (unpub. observ.)
aUnderlined bases are LNA. meC, 5-methylcytosine. All oligomers are shown from 5′ to 3′.
bReference Tm values are for analogous DNA oligonucleotides.
cND, melting temperature not detected; NP, analysis not performed. ∆Tm and ∆Tm/LNA base could thus not be calculated.






synthesis of DNA or RNA, allowing PS link-
ages to be added routinely (Kumar et al., 1998).
Complete substitution of phosphodiester link-
ages with PS linkages has also been noted to
improve the pharmacokinetic properties of an-
tisense oligonucleotides (Geary et al., 2001). It
is reasonable to believe that LNA-containing
oligomers will also need to be modified with
PS linkages to achieve in vivo efficacy, though
animal studies will be necessary to establish if
this truly is the case for LNA-containing
chimeric oligonucleotides.
The choice of whether or not to exploit the
potential for RNase H activation influences
how antisense activity will be examined on a
case-by-case basis. LNA oligomers that con-
tain DNA segments that can activate RNase H
will cause RNA to be degraded, allowing effi-
cacy to be judged by northern analysis. LNA
oligomers that cannot activate RNase H can be
evaluated by examining the expression of the
protein target or by measuring its activity. As
with any antisense experiment, use of control
oligonucleotides that contain mismatched
bases is necessary to support the belief that an
effect is specific, i.e., due to binding to the
intended mRNA target.
Troubleshooting
When oligonucleotides are introduced into
cells, they may prove to be toxic. This toxicity
could be due to successful inhibition of the
target gene function. However, toxicity could
also be due to (1) binding to one or more
nontarget proteins, (2) hybridization to one or
more nontarget nucleic acid sequences, or (3)
poisoning of the cells by small molecule impu-
rities or endotoxins. The primary consideration
is that the observed effects should be consistent
with the biology of the system being examined.
If cell death is observed, LNAs can be puri-
fied by desalting to remove small molecule
contaminants. Alternatively, a fresh synthesis
of LNA can be performed to determine if newly
made material behaves similarly. Toxicity
could also be caused by improper choice of
transfection conditions, reagent concentra-
tions, cell line, or lipids. The window between
the conditions that produce optimal LNA de-
livery and those that cause cells to die is likely
to be small. Use of fluorophore-labeled LNAs
provides a convenient method for evaluating
the success of a given protocol. The authors
have also observed that some syntheses of
LNAs are relatively insoluble. If this occurs,
the experimenter should consult with the manu-
facturer.
Anticipated Results
There are many effective antisense oligonu-
cleotides that do not contain LNA bases. Why
use LNA? Why not stay with standard oligonu-
cleotide designs? The use of LNAs is only three
years old, and there are no definitive answers
to these questions. However, it is reasonable to
speculate that the ability of LNA bases to dra-
matically improve the affinity of binding might
increase the potency, specificity, and predict-
ability of antisense action. The resulting in-
crease in efficacy would allow “knock down”
phenotypes to be generated more easily, and the
fact that LNA bases can be easily incorporated
into oligonucleotides allows this hypothesis to
be readily tested.
Microscopic examination of the delivery of
a fluorophore-labeled LNA is a useful demon-
stration that transfection conditions are pro-
moting LNA uptake by cells. In the authors’
experience, micrographs show that LNA is dis-
tributed throughout the cytoplasm and nucleus,
with some punctate staining indicating areas of
high concentration.
Time Considerations
LNAs normally can be obtained within 2
weeks of placing an order with Proligo. LNAs
should completely dissolve in water within 20
min. Quantification of LNA concentration by
UV spectrophotometry and determination of a
Tm value should take ∼2 hr. Transfection of
LNA into cells should require an additional 2
to 4 hr. The time required for observation of a
phenotype will vary from hours to days, de-
pending on the gene being targeted.
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